Kidney injury may be less among patients with chronic kidney disease and atrial fibrillation taking apixaban versus warfarin for anticoagulation, new research suggests.
Your search for apixaban returned 47 results
Less knowledge about OTC products with potentially serious interactions linked to increased use
Apixaban is a direct oral anticoagulant that relies less on kidney excretion.
Among patients with cancer starting chemotherapy who are at intermediate-to-high risk, rates of venous thromboembolism are significantly lower for thromboprophylaxis with apixaban vs placebo.
Apixaban dominated enoxaparin and edoxaban; rivaroxaban was slightly more effective than apixaban
No substantial differences seen for other outcomes or for other direct oral anticoagulant comparisons
Compared with other DOACs, rivaroxaban linked to higher rates of GI bleeding overall and in an analysis restricted to patients with atrial fibrillation
Major adverse cardiopulmonary outcomes not reduced with aspirin, apixaban versus placebo for clinically stable COVID-19 outpatients
Non-vitamin K oral anticoagulants exhibit variable effects on coagulation assays, according to a new study.
Reversal of anticoagulant activity of apixaban and rivaroxaban seen in older healthy participants
- Loading...
